subject: Mylan Inc. - Swot Analysis - Market Reserach Report On Aarkstore Enterprise. [print this page] Mylan Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Mylan Inc. - SWOT Analysis examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Mylan is the third largest generic pharmaceutical company in the world by revenues. It is engaged in the development, licensing, manufacture, marketing and distribution of generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients. Mylan primarily operates in the US. It is headquartered in Canonsburg, Pennsylvania, and employed 15,000 people as of December 2008. The company recorded total revenues of $5,137.6 million during the financial year (FY) ended December 2008. The operating profit of the company was $297.9 million in FY2008. The net loss was $320.2 million in FY2008. As the company changed its financial year ending from March to December in 2007. The full year profit/loss data is not available for FY2007.
Scope of the Report
- Provides all the crucial information on Mylan Inc. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting Mylan Inc. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Mylan Inc.
-Data is supplemented with details on Mylan Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Mylan Inc.
Reasons to Purchase
- Support sales activities by understanding your customers businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors business structure, strategy and prospects
- Obtain the most up to date company information available"
Table of Contents :
This product typically includes the following sections:
